Navigation Links
EntreMed Reports Fourth Quarter and Year-End 2011 Financial Results
Date:3/10/2012

ations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time.  Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed.

Actual results could differ materially from those currently anticipated due to a number of factors, including: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; our history of losses and expectation of incurring continued losses; the risk that our stockholders may not approve our recent financing transaction and our ability to repay the indebtedness incurred in connection with issuance and sale of the convertible notes if such notes are not converted into shares of common stock; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility of our common stock; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidate; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; declines in actual sales of Thalomid® resulting in reduced royalty payments; risks associated with our product candidates; any early-stage products under development; results in preclinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; the lack of success in the clinical development of any of our products; dependence on third parties; and risks relating to the commercialization, if any, of our  proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks); and our ability to comp
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMeds ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients
2. EntreMed Reports Fourth Quarter and Year-End 2010 Financial Results
3. EntreMed Reports Receipt of Third Quarter Royalty Payment
4. EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
5. EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma
6. EntreMed to Present at the New York Society of Security Analysts Industry Conference
7. EntreMeds MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
8. EntreMed Reports Third Quarter 2008 Financial Results
9. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
10. EntreMed to Present at BioPartnering Europe Conference
11. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 LayerBio, Inc., an MIT ... its first round of seed financing from friends and ... efforts to develop a novel sustained-release product for ophthalmology. ... investors and their commitment to this important work," said ... is one of many areas in which innovations in ...
(Date:7/29/2014)... (PRWEB) July 30, 2014 “PharmaSphere: ... Equity and Venture Capital Funding” report provides in-depth ... the private equity and venture capital segments of ... are expected to have significant impact on the ... and globally. Furthermore, the report identifies regions of ...
(Date:7/29/2014)... 29, 2014 The advanced optical methods ... that are driving a revolution in the neurosciences were ... journal published by SPIE, the international society for ... with the launch of the BRAIN Initiative in the ... lay out a vision for and provide examples of ...
(Date:7/29/2014)... 29, 2014 Human Longevity, Inc. (HLI), a ... on extending the healthy, high performance human life span, ... Ph.D., an expert in machine learning and machine translation ... HLI from Google where he was Distinguished Research Scientist ... directly to HLI Co-Founder and CEO, J. Craig ...
Breaking Biology Technology:Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 2Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 4SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 2SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 4Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3
... SEATTLE, July 9 Cell Therapeutics, Inc. (CTI),(Nasdaq and ... Providers Act of 2008, as passed by the U.S. ... Senate on July 9, 2008, would,continue the 2007 reimbursement ... a start date of July,1, 2008. In December, Congress ...
... Compensatory Award Will Now Proceed -, MADISON, N.J., July ... motion for judgment as a matter of law on the,punitive ... v.,Wyeth, in the U.S. District Court, Eastern District of Arkansas, ... damages award of,$19,360,000 rendered by the Little Rock jury last ...
... ARBOR, Mich., July 9 Terumo Cardiovascular Systems,(Terumo ... infringement complaint in,Germany against two affiliates of Maquet ... Vertriebs und Service Deutschland GmbH. The complaint,alleges that ... Vessel Harvesting Systems, infringe a patent for which ...
Cached Biology Technology:Congress Extends 2007 Reimbursement Rates for Radioimmunotherapies for 18 Months 2Congress Extends 2007 Reimbursement Rates for Radioimmunotherapies for 18 Months 3Congress Extends 2007 Reimbursement Rates for Radioimmunotherapies for 18 Months 4Wyeth's Motion to Overturn Punitive Damages Award Granted by Arkansas Court 2Wyeth's Motion to Overturn Punitive Damages Award Granted by Arkansas Court 3Terumo Cardiovascular Systems Files Patent Infringement Complaint Against Maquet Affiliates 2
(Date:7/30/2014)... HIV infection could be as simple as inserting a ... University of Washington bioengineers have discovered a potentially faster ... from contracting HIV. Their method spins the drug into ... moisture, releasing higher doses of the drug than possible ... , "This could offer women a potentially more effective, ...
(Date:7/30/2014)... humans figured out how to create colors, nature had ... wings of many different hues, for example. Now scientists ... environmentally friendly way to make colored plastics. Their paper ... of materials rather than dyes, to produce color ... , N. Asger Mortensen, Anders Kristensen and colleagues point ...
(Date:7/30/2014)... been awarded the Scientific Committee on Antarctic Research,s ... , SCAR, an inter-disciplinary international science body, initiates, ... in the Antarctic region, and on the role ... The organisation also provides scientific advice about Antarctica ... the region. , The medal is open internationally ...
Breaking Biology News(10 mins):Dissolvable fabric loaded with medicine might offer faster protection against HIV 2Dissolvable fabric loaded with medicine might offer faster protection against HIV 3
... The Scripps Research Institute has been awarded a $500,000 ... pair of genetic mutations that could lead to a new ... and fatal neurodegenerative disorder. Philip LoGrasso, PhD, a professor ... Scripps Florida, is the principal investigator for the project. ...
... DeKalb, Ill. -- It,s safe to say Northern Illinois ... cats. She keeps two tabbies at her Hampshire, Ill. home. ... anything but cute and cuddly -- the prehistoric saber-tooths. ... of Kansas and fossil hunter John Babiarz -- are editors ...
... warming and its impact on our environment have left ... humans produce. Now, Tel Aviv University researchers are doing ... growing forests in the most unlikely place deep ... such as a local plant species, recycled sewage water ...
Cached Biology News:Scripps Research scientist awarded $500,000 grant to study Parkinson's disease 2Scripps Research scientist awarded $500,000 grant to study Parkinson's disease 3NIU biologist Virginia Naples is helping put new face on ferocious saber-tooth cats 2NIU biologist Virginia Naples is helping put new face on ferocious saber-tooth cats 3Growing something out of nothing 2
RECOMBINANT EQUINE TNF ALPHA Product Type: Recombinant Protein...
... contains 5 ml of DETACHaBEAD 19 ... Dynabeads CD19 (Pan B). B ... B) and released with DETACHaBEAD CD19 ... are suitable for applications such as ...
... Buffers are supplied as 10X concentrated solutions. REact ... each of the REact buffers and one 250 ... of four 1 ml vials of REact 1 ... Buffer four 1 ml vials of REact 3 ...
... The Vybrant Apoptosis Assay Kit #4 ... changes that occur in the permeability of ... of both YO-PRO-1 and propidium iodide nucleic ... the plasma membranes of apoptotic cells and ...
Biology Products: